Is Progyny (PGNY) overvalued or fairly valued?

MarketChacha shows Progyny's valuation in context — a trailing P/E of about 40.4, a forward P/E of about 13.8, a price-to-book of about 5.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Progyny's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (3.31×) from reported figures — education, not a rating.

What is Progyny's revenue?

Progyny reported revenue of $1.3B for FY2025, with net profit of $58.5M, per official filings.

What is the share price of Progyny (PGNY)?

Progyny last traded at $31.12 (-3.5% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Progyny

PGNY · NYSE · Healthcare · United States

$31.12-3.5%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 7:36 PM

Snapshot

TickerPGNY

ExchangeNYSE

SectorHealthcare

IndustryHealthcare Plans

CountryUnited States

Employees835

HeadquartersNew York, United States

Market cap$2.4B

P/E (TTM)40.4

P/B5.5

Volume619.39K

Websitewww.progyny.com

Filings tracked4

About Progyny

Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

Profile as reported by Yahoo Finance.

Who owns it

Insiders2.0%
Institutions98.0%
Public & other0.0%

427 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.15.32%
FMR, LLC8.30%
Vanguard Portfolio Management LLC6.76%
Vanguard Capital Management LLC4.44%
State Street Corporation3.93%
Ameriprise Financial, Inc.3.61%
Fort Washington Investment Advisors, Inc.3.25%
Wellington Management Group, LLP2.92%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion3.31×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend5.7% → 4.5%

Margin has held broadly steady over the period — stable profitability.

Growth qualityrev 9% · PAT -3%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $350.6M · EPS 0.52

Est. earnings growth +16.2%

Next fiscal year

Rev $1.5B · EPS 2.25

Est. earnings growth +9.3%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$16.1052-wk range$33.07

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Market cap

$2.4B

Day change

-3.5%

P/E (TTM)

40.4

Fwd P/E

13.8

P/B

5.5

Beta

1.02

Revenue (FY2025)

$1.3B

Net margin

4.5%

ROE

11.3%

Revenue CAGR (2y)

+8.8%

Profit CAGR (2y)

-2.9%

EPS (FY2025)

0.65

Net profit (FY2025)

$58.5M

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about PGNY

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$1.3B	$58.5M	0.65	4.5%	11.3%
FY2024	$1.2B	$54.3M	0.57	4.7%	12.9%
FY2023	$1.1B	$62.0M	0.62	5.7%	11.2%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$328.5M	$24.2M	0.29	7.4%
2025Q4	$318.4M	$12.5M	0.14	3.9%
2025Q3	$313.3M	$13.9M	0.15	4.4%
2025Q2	$332.9M	$17.1M	0.19	5.1%
2025Q1	$324.0M	$15.1M	0.17	4.6%
2024Q4	$298.4M	$10.5M	0.12	3.5%
2024Q3	$286.6M	$10.4M	0.11	3.6%
2024Q2	$304.1M	$16.5M	0.17	5.4%
2024Q1	$278.1M	$16.9M	0.17	6.1%
2023Q4	$269.9M	$13.5M	0.13	5.0%
2023Q3	$280.9M	$15.9M	0.16	5.7%
2023Q2	$279.4M	$15.0M	0.15	5.4%
2023Q1	$258.4M	$17.7M	0.18	6.8%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Bylaw/charter change, Shareholder vote results
SEC5/27/2026material
8-K — Other events
SEC5/26/2026material
10-Q filing
SEC5/8/2026
8-K — Results of operations, Reg FD disclosure
SEC5/7/2026material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.